0001193125-26-151891
SEC filingAlamar Biosciences is a commercial-stage proteomics company offering the ARGO HT System for ultra-sensitive protein biomarker detection, with 2025 revenue of $74.2M (195% YoY growth) and an IPO of 9.375M shares at $16.00 midpoint to fund growth.
Alamar Biosciences has rapidly scaled its proteomics platform since launching the ARGO HT System in January 2024, achieving $74.2M revenue in 2025 (195% YoY growth) from 102 instruments installed across 300+ customers in 25 countries, including all top 10 biopharma companies. The razor-blade model drives recurring consumables revenue (>50% of 2025 total, >$400K average annual pull-through per instrument), positioning Alamar for sustained growth in the $4.1B advanced proteomics market (projected $20B by 2035). NULISA technology's attomolar sensitivity and multiplexing differentiate it from competitors like Olink and Quanterix, enabling Precision Proteomics for neurology/immunology panels with >100 publications validating performance.
The IPO raises $133.2M net (9.375M shares at $16 midpoint, 14.4% dilution) for sales expansion, manufacturing scale-up, and ARGO HT/DX development (FDA submission 2027). Post-IPO capitalization shows 64.9M shares outstanding, with insiders/affiliates retaining ~55.5% control. Qiming (18.9%), Illumina (11%), and Sherpa (8.5%) anchor ownership.
Key risks include Olink patent litigation (IPR decision March 2026 upheld claims; district court ongoing), single-source supplier dependence for antibodies/instruments, and revenue concentration in research institutions reliant on NIH funding. Losses narrowed to $29.8M in 2025 from $47.1M (gross margin 56% vs 34%), but cash burn persists ($30M cash, $9.8M debt). Experienced leadership (CEO Luo founded acquired ACD) supports execution, but limited history and manufacturing complexity pose execution risks. Investors should weigh proteomics market potential against litigation/supply chain vulnerabilities.